The T-cell therapy Market valued for $2.82 Billion in 2022 and is estimated to reach $15.18 Billion by 2032, exhibiting a CAGR of 18.3% from 2023 to 2032. T cells are a type of immune cell that plays a critical role in the body's defense against disease. T-cell therapy involves the manipulation of a patient's T cells outside the body, often using genetic engineering techniques, to enhance their ability to recognize and attack cancer cells or other disease-causing cells. These modified T cells are then infused back into the patient's body, where they can seek out and destroy cancer cells.
The T-cell therapy market is being driven by several key factors such as the Increasing prevalence of cancer resulting in a greater demand for effective treatment options. T-cell therapy has emerged as a promising approach for treating cancer and other diseases Including autoimmune disorders and viral infections, driving its adoption and growth. Additionally, the aging population is another factor that is driving the demand for T-cell therapies. The geriatric population is more prone to developing cancer and other diseases, creating a larger pool of potential patients for T-cell therapy. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized T-cell therapies, which are likely to drive the market growth. These therapies have shown promising results in clinical trials, leading to Increased investment in research and development activities.
Moreover, the rise in key strategies adopted by the key market players such as agreement, and collaborations further drives the growth of the market during the forecast period. For instance, on February 10, 2021, AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Furthermore, a rise in approvals from regulatory organizations is further providing opportunity for market growth. For instance, on October 17, 2022, Gilead Company, a biopharmaceutical company received the European Commission (EC) approval for the use of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first line chemoimmunotherapy. Thus, the adoption of such strategies by key manufacturers can potentially Increase the demand and adoption of cell therapy technology and provide lucrative opportunity to market growth.
However, side effects associated with cellular therapies such as cytokine release syndrome and neurotoxicity, which can limit its use. Furthermore, the high cost of treatment is also a significant challenge for patients and healthcare providers and can limit the adoption of these therapies. These factors collectively have hindered the market growth to some extent.
The global T-cell therapy market is segmented into therapy type, indication, end user and region. As per therapy type, the market is categorized into CAR T-cell Therapy and T Cell Receptor (TCR)-Based. The CAR T-cell Therapy segment is further categorized by product type into Axicabtagene Ciloleucel, Tisagenlecleucel, Bexucabtagene Autoleucel and Others (Ciltacabtagene autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel). According to indication, the market is segregated into Lymphoma, Acute Lymphocytic Leukemia, and Others (Multiple Myeloma, Melanoma). According to end user, the market is segregated into Hospitals and Cancer Treatment Centers. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).
Major key players that operate in the global T-cell therapy market are Novartis AG, Autolus Therapeutics, Caribou Biosciences, Inc, Gilead Sciences, Immunocore Ltd., Celyad Oncology, Cartesian Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company and Cellectis, Inc. The key players operating in the market have adopted product approval, agreement, and collaboration as their key strategies to expand their product portfolio.
The T-cell therapy market is being driven by several key factors such as the Increasing prevalence of cancer resulting in a greater demand for effective treatment options. T-cell therapy has emerged as a promising approach for treating cancer and other diseases Including autoimmune disorders and viral infections, driving its adoption and growth. Additionally, the aging population is another factor that is driving the demand for T-cell therapies. The geriatric population is more prone to developing cancer and other diseases, creating a larger pool of potential patients for T-cell therapy. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized T-cell therapies, which are likely to drive the market growth. These therapies have shown promising results in clinical trials, leading to Increased investment in research and development activities.
Moreover, the rise in key strategies adopted by the key market players such as agreement, and collaborations further drives the growth of the market during the forecast period. For instance, on February 10, 2021, AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Furthermore, a rise in approvals from regulatory organizations is further providing opportunity for market growth. For instance, on October 17, 2022, Gilead Company, a biopharmaceutical company received the European Commission (EC) approval for the use of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first line chemoimmunotherapy. Thus, the adoption of such strategies by key manufacturers can potentially Increase the demand and adoption of cell therapy technology and provide lucrative opportunity to market growth.
However, side effects associated with cellular therapies such as cytokine release syndrome and neurotoxicity, which can limit its use. Furthermore, the high cost of treatment is also a significant challenge for patients and healthcare providers and can limit the adoption of these therapies. These factors collectively have hindered the market growth to some extent.
The global T-cell therapy market is segmented into therapy type, indication, end user and region. As per therapy type, the market is categorized into CAR T-cell Therapy and T Cell Receptor (TCR)-Based. The CAR T-cell Therapy segment is further categorized by product type into Axicabtagene Ciloleucel, Tisagenlecleucel, Bexucabtagene Autoleucel and Others (Ciltacabtagene autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel). According to indication, the market is segregated into Lymphoma, Acute Lymphocytic Leukemia, and Others (Multiple Myeloma, Melanoma). According to end user, the market is segregated into Hospitals and Cancer Treatment Centers. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).
Major key players that operate in the global T-cell therapy market are Novartis AG, Autolus Therapeutics, Caribou Biosciences, Inc, Gilead Sciences, Immunocore Ltd., Celyad Oncology, Cartesian Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company and Cellectis, Inc. The key players operating in the market have adopted product approval, agreement, and collaboration as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the t-cell therapy market analysis from 2022 to 2032 to identify the prevailing t-cell therapy market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the t-cell therapy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Therapy Type
- CAR T-Cell therapy
- Product Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By End User
- Hospitals
- Cancer Treatment Centers
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
Key Market Players
- Caribou Biosciences, Inc
- Celyad Oncology
- Gilead Sciences, Inc.
- Novartis AG
- Cellectis, Inc.
- Johnson & Johnson
- Autolus Therapeutics
- Bristol-Myers Squibb Company
- Immunocore Ltd.
- Cartesian Therapeutics, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: T-CELL THERAPY MARKET, BY THERAPY TYPE
CHAPTER 5: T-CELL THERAPY MARKET, BY INDICATION
CHAPTER 6: T-CELL THERAPY MARKET, BY END USER
CHAPTER 7: T-CELL THERAPY MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'T-Cell therapy Market,' The t-cell therapy market was valued at $2.8 billion in 2022, and is estimated to reach $15.2 billion by 2032, growing at a CAGR of 18.3% from 2023 to 2032.The T-cell therapy market is likely to experience a significant growth rate of 18.3% from 2023-2032 owing to increasing market demand of CAR-T cell therapy segment.
T-cell therapy is a type of immunotherapy that harnesses the power of a patient's own immune system to fight cancer. This therapy involves the extraction of T cells from the patient's blood, which are then genetically modified or activated in the laboratory to recognize and attack cancer cells. Once the T cells are reinfused back into the patient's body, they seek out and destroy cancer cells. T-cell therapy has shown remarkable success in the treatment of hematological malignancies, such as leukemia and lymphoma, and is being researched for the treatment of solid tumors.
Key factors driving the growth of the T-cell therapy market is rise in prevalence cancer cases such as lymphoma, acute lymphocytic leukemia, myeloma and Melanoma. For instance, according to WHO, 19,858 cases of Hodgkin lymphoma and 50,918 cases of multiple myeloma were reported in Europe in 2020. The incidence of blood cancer continues to grow, which has increased by 40% in the past 10 years. In addition, rise in presence of multiple healthcare facilities and growing awareness regarding gene therapy, is further anticipated to drive market growth.
Further, as the global geriatric population continues to grow, the incidence of cancer among this demographic increases significantly. Aging is a known risk factor for cancer development, with the geriatric population being more prone to developing various types of cancer. This demographic often faces unique challenges in cancer treatment due to factors such as reduced organ function, comorbidities, and decreased tolerance to aggressive treatments like chemotherapy and radiation therapy.
T cell therapy offers a promising solution for the geriatric population as it harnesses the patient's own immune system to target and eliminate cancer cells. Unlike traditional treatments, T cell therapy can be tailored to individual patients, making it a potentially safer and more effective option for older individuals. The ability of T cell therapy to induce long-lasting responses and potentially provide a cure for some patients is particularly valuable in the geriatric population, where maintaining a good quality of life and minimizing treatment-related toxicity are crucial considerations and thus is potentially driving the market growth.
Moreover, the T cell therapy market has witnessed a significant increase in investment and funding from both private and public sectors. Pharmaceutical companies, biotechnology firms, and venture capitalists are recognizing the immense potential of T cell therapy and investing heavily in its development. This increased funding has accelerated research and development efforts, clinical trials, and manufacturing capabilities, driving the growth of the T cell therapy market. For instance, according to the American Institute of Cancer Research (AICR) reports, American Institute of Cancer Research reports (AICR) has funded more than $110 million for research through its own grant program, continued federal government investment in cancer research.
Furthermore, the market also offers growth opportunities to the key players in the market. Many developing regions offer lucrative opportunities to key players of T-cell therapy market owing to high population base, increase in demand of efficient treatments with minimum side effects and rise healthcare spending. In addition, rise in disposable income and medical tourism fuels the growth of T-cell therapy market.
The global T-cell therapy market is segmented into therapy type, indication, end user and region. As per therapy type, the market is categorized into CAR T-cell therapy and T-cell receptor (TCR)-based. The CAR T-cell Therapy segment is further categorized by product type into Axicabtagene Ciloleucel, Tisagenlecleucel, Bexucabtagene Autoleucel and Others (Ciltacabtagene autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel). According to indication, the market is segregated into Lymphoma, Acute Lymphocytic Leukemia, and Others (Multiple Myeloma, Melanoma). According to end user, the market is segregated into Hospitals and Cancer Treatment Centers. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).
The key players profiled in the study include Novartis AG, Autolus Therapeutics, Caribou Biosciences, Inc, Gilead Sciences, Immunocore Ltd., Celyad Oncology, Cartesian Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company and Cellectis, Inc. The key players operating in the market have adopted product approval, agreement, and collaboration as their key strategies to expand their product portfolio.
Key Market Insights
- On the basis of therapy type, the CAR T-cell therapy segment dominated the market in terms of revenue in 2022.
- On the basis of indication, the Lymphoma segment dominated the market in terms of revenue in 2022. However, the others segment is anticipated to grow at the highest CAGR during the forecast period.
- On the basis of end user, the hospitals segment dominated the market in terms of revenue in 2022.
- Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Caribou Biosciences, Inc
- Celyad Oncology
- Gilead Sciences, Inc.
- Novartis AG
- Cellectis, Inc.
- Johnson & Johnson
- Autolus Therapeutics
- Bristol-Myers Squibb Company
- Immunocore Ltd.
- Cartesian Therapeutics, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
